Quantum Biopharma Ltd (QNTM) Stock Price, Quote & News

Company Profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical enti...

Industry: Biotechnology

Sector: Healthcare

Phone: 833 571 1811

Website: www.quantumbiopharma.com

Address:

1 Adelaide Street East, Suite 801, Toronto, Canada

deedee12 Sep. 2 at 1:58 AM

$QNTM 👎🏼👎🏼👎🏼👎🏼

0 · Reply

focafoca99 Sep. 2 at 12:58 AM

$QNTM has applied to voluntarily delist its Class B shares from the Canadian Securities Exchange.

0 · Reply

Merlintrader Sep. 1 at 12:41 PM

$QNTM Quantum BioPharma ($QNTM) Stock Hub 2026: FDA Cleared Lucid-MS for Phase 2 and Q2 Strengthened Equity and Liquidity https://www.merlintrader.com/quantum-biopharma-stock-hub/

0 · Reply

RollingPins Aug. 31 at 8:31 PM

$QNTM more

0 · Reply

NetworkNewsWire Aug. 31 at 7:56 PM

NetworkNewsBreaks – $QNTM $QNTM.CN Draws ‘Buy’ Rating on Lucid-MS Potential https://ibn.fm/80kGB

0 · Reply

RollingPins Aug. 31 at 4:39 AM

$QNTM

0 · Reply

FrostyOrbit Aug. 30 at 9:08 PM

$QNTM Quantum BioPharma Ltd. (NASDAQ: QNTM) a small-cap biotech developing drug candidates including Lucid-MS…

0 · Reply

NetworkNewsWire Aug. 27 at 7:58 PM

InvestorNewsBreaks – $QNTM $QNTM Moves Myelin-Protecting MS Therapy to Phase 2 Development https://ibn.fm/1H78r

0 · Reply

nopennys Aug. 26 at 8:14 PM

$QNTM $GNS $CYCU 🤡 told you

0 · Reply

Mark_Venture Aug. 26 at 12:03 AM

$QNTM is about to start a phase 2 trial of their drug that is designed to do something totally unprecedented, which is to protect and regrow myelin in MS patients. This would meet a huge, unmet need. I spoke with Zeeshan again today, and he told me there will be 8 trial locations here in the US. I'm hoping one of them is close to Los Angeles.

1 · Reply

Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange

2026-08-31T11:10:12.000Z - 1 day ago

Quantum Group initiated with a Buy at Rodman & Renshaw

Fri, 21 Aug 2026 19:00:00 -0400 - 11 days ago

Quantum Biopharma Provides Corporate Update

Fri, 14 Aug 2026 07:00:00 -0400 - 18 days ago

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

Mon, 10 Aug 2026 07:00:00 -0400 - 22 days ago

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

Thu, 30 Jul 2026 00:18:00 -0400 - 4 weeks ago

Quantum BioPharma Announces Closing of Debt Settlement

Mon, 20 Jul 2026 19:00:00 -0400 - 6 weeks ago

Quantum BioPharma Announces Intention to Settle Debt

Tue, 07 Jul 2026 19:00:00 -0400 - 2 months ago

Quantum BioPharma Provides Corporate Update

Fri, 26 Jun 2026 08:30:00 -0400 - 2 months ago

NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis

Thu, 25 Jun 2026 08:30:00 -0400 - 2 months ago

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

Tue, 23 Jun 2026 08:30:00 -0400 - 2 months ago

Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach

Tue, 02 Jun 2026 08:00:00 -0400 - 3 months ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Tue, 02 Jun 2026 07:40:00 -0400 - 3 months ago

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

Mon, 01 Jun 2026 19:30:00 -0400 - 3 months ago

Quantum BioPharma Provides Corporate Update

Mon, 18 May 2026 03:00:00 -0400 - 3 months ago

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

Thu, 07 May 2026 07:00:00 -0400 - 4 months ago

Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

Mon, 27 Apr 2026 19:45:00 -0400 - 4 months ago

Quantum BioPharma Provides Corporate Update

Wed, 22 Apr 2026 09:16:00 -0400 - 4 months ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

2026-04-01T12:25:14.000Z - 5 months ago

Quantum BioPharma submits Lucid-21-302 new drug application to the FDA

Wed, 01 Apr 2026 08:02:00 -0400 - 5 months ago

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

2026-03-30T12:47:57.000Z - 5 months ago

Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial

2026-03-30T12:28:19.000Z - 5 months ago

Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial

Mon, 30 Mar 2026 07:50:00 -0400 - 5 months ago

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

Fri, 27 Mar 2026 19:30:00 -0400 - 5 months ago

Quantum Biopharma Provides Corporate Update

Fri, 27 Mar 2026 08:10:00 -0400 - 5 months ago

Quantum Biopharma's 2025 Audited Year End Financial Results Maintain ‘No Going Concern' Status

Mon, 23 Mar 2026 08:24:00 -0400 - 5 months ago

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

Fri, 20 Mar 2026 19:35:00 -0400 - 5 months ago

Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

Wed, 11 Mar 2026 19:55:00 -0400 - 6 months ago

Quantum BioPharma Provides Corporate Update

Thu, 19 Feb 2026 19:29:00 -0500 - 6 months ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

Thu, 19 Feb 2026 12:00:00 -0500 - 6 months ago

Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

Tue, 17 Feb 2026 13:55:00 -0500 - 7 months ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors

Tue, 17 Feb 2026 12:59:00 -0500 - 7 months ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Tue, 17 Feb 2026 09:41:00 -0500 - 7 months ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors

Thu, 12 Feb 2026 16:02:00 -0500 - 7 months ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

Tue, 03 Feb 2026 13:12:00 -0500 - 7 months ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Mon, 02 Feb 2026 10:46:00 -0500 - 7 months ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors

Tue, 27 Jan 2026 13:42:00 -0500 - 7 months ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Dec 23, 2025, 8:00 AM EST - 9 months ago

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

Mon, 22 Dec 2025 09:00:00 -0500 - 9 months ago

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

Dec 10, 2025, 8:00 PM EST - 9 months ago

Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update

2025-12-01T12:15:18.000Z - 9 months ago

Quantum BioPharma announces airing of news segment on manipulation lawsuit

Nov 27, 2025, 4:00 PM EST - 9 months ago

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC

Nov 26, 2025, 9:30 AM EST - 9 months ago

Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

2025-11-07T12:12:42.000Z - 10 months ago

Quantum BioPharma reports Q3 EPS ($1.25) vs. (4.37) last year

2025-11-07T12:11:35.000Z - 10 months ago

Quantum BioPharma sees cash runway beyond March 2027

Nov 7, 2025, 7:00 AM EST - 10 months ago

Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

Oct 31, 2025, 7:51 PM EDT - 10 months ago

Quantum BioPharma Ltd. Provides Corporate Update

Oct 29, 2025, 9:00 PM EDT - 10 months ago

Quantum BioPharma Ltd. Announces Corporate Updates

Oct 23, 2025, 8:15 AM EDT - 11 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

2025-10-20T12:40:40.000Z - 11 months ago

Quantum BioPharma announces expiration of warrants held by hedge funds

Oct 20, 2025, 8:30 AM EDT - 11 months ago

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

Oct 9, 2025, 6:00 PM EDT - 11 months ago

Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM

Oct 8, 2025, 8:00 AM EDT - 11 months ago

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Oct 7, 2025, 11:00 AM EDT - 11 months ago

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View

Oct 3, 2025, 7:00 AM EDT - 11 months ago

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

Oct 2, 2025, 7:57 AM EDT - 11 months ago

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

Oct 1, 2025, 7:50 AM EDT - 11 months ago

Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

Sep 29, 2025, 7:40 AM EDT - 1 year ago

Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

Sep 26, 2025, 8:00 PM EDT - 1 year ago

Quantum BioPharma Announces Corporate Updates

Sep 24, 2025, 8:30 AM EDT - 1 year ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025

Sep 18, 2025, 8:10 AM EDT - 1 year ago

Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance

Sep 12, 2025, 7:50 AM EDT - 1 year ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT

Sep 10, 2025, 7:00 AM EDT - 1 year ago

Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target

Aug 11, 2025, 6:32 PM EDT - 1 year ago

Quantum BioPharma Announces Update to Previously Announced Private Placement

Aug 11, 2025, 7:40 AM EDT - 1 year ago

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

Aug 5, 2025, 7:34 AM EDT - 1 year ago

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

Aug 4, 2025, 7:33 AM EDT - 1 year ago

Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing

Jul 31, 2025, 7:24 AM EDT - 1 year ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO

deedee12 Sep. 2 at 1:58 AM

$QNTM 👎🏼👎🏼👎🏼👎🏼

0 · Reply

focafoca99 Sep. 2 at 12:58 AM

$QNTM has applied to voluntarily delist its Class B shares from the Canadian Securities Exchange.

0 · Reply

Merlintrader Sep. 1 at 12:41 PM

$QNTM Quantum BioPharma ($QNTM) Stock Hub 2026: FDA Cleared Lucid-MS for Phase 2 and Q2 Strengthened Equity and Liquidity https://www.merlintrader.com/quantum-biopharma-stock-hub/

0 · Reply

RollingPins Aug. 31 at 8:31 PM

$QNTM more

0 · Reply

NetworkNewsWire Aug. 31 at 7:56 PM

NetworkNewsBreaks – $QNTM $QNTM.CN Draws ‘Buy’ Rating on Lucid-MS Potential https://ibn.fm/80kGB

0 · Reply

RollingPins Aug. 31 at 4:39 AM

$QNTM

0 · Reply

FrostyOrbit Aug. 30 at 9:08 PM

$QNTM Quantum BioPharma Ltd. (NASDAQ: QNTM) a small-cap biotech developing drug candidates including Lucid-MS…

0 · Reply

NetworkNewsWire Aug. 27 at 7:58 PM

InvestorNewsBreaks – $QNTM $QNTM Moves Myelin-Protecting MS Therapy to Phase 2 Development https://ibn.fm/1H78r

0 · Reply

nopennys Aug. 26 at 8:14 PM

$QNTM $GNS $CYCU 🤡 told you

0 · Reply

Mark_Venture Aug. 26 at 12:03 AM

1 · Reply

FickleFin Aug. 24 at 2:43 PM

$QNTM $GME $GNS . Always paying themselves before finishing anything.

0 · Reply

FickleFin Aug. 22 at 11:06 AM

$QNTM $GNS $GME $NWBO $MMTLP 🥴🥴🥴

1 · Reply

Gentleman4599 Aug. 22 at 4:49 AM

$QNTM

0 · Reply

Rambler1111 Aug. 22 at 12:20 AM

$QNTM not really that much of an update today. Whatever!!!

0 · Reply

Merlintrader Aug. 20 at 12:27 PM

$QNTM The interim financials for the six months to June 30, filed on August 13, put 3.65 million dollars of cash next to 5.89 million dollars of digital assets: the crypto position on the balance sheet is larger than the cash position. Total liabilities were 8.30 million, including 2.23 million of warrant liability and 1.73 million of derivative liabilities. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/quantum-biopharma-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=giro-20ago2026

0 · Reply

James23db Aug. 19 at 7:42 PM

$QNTM manipulated on both sides of the coin

0 · Reply

NetworkNewsWire Aug. 19 at 7:17 PM

$QNTM Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves https://ibn.fm/syxOj

0 · Reply

NetworkNewsWire Aug. 19 at 5:15 PM

BioMedNewsBreaks — $QNTM $QNTM.CN Explores Myelin Protection as New Focus in MS Treatment https://ibn.fm/4ddys

0 · Reply

FickleFin Aug. 19 at 1:41 PM

$QNTM $GNS $GME $NWBO $MMTLP exit liquidity is key. 😉😄

0 · Reply

MM1968 Aug. 19 at 11:06 AM

$GNS $MMTLP $NWBO $QNTM We will see. https://x.com/CryptosR_Us/status/2089406150467100792/video/1?s=46

1 · Reply

MM1968 Aug. 19 at 10:29 AM

$GNS watch for news today from executive gathering from the Whitehouse. Atkins and Selig with industry executives. Then the follow up tomorrow with meeting chaired by CFTC. As I have stated previously, Genius Law mandates all currency and monetization vehicles on chain and tokenized. That includes stocks. Attached is a letter from RH CEO. I know he executed halt of GME buy button. Please read his letter and determine whether he was spoken to. He acknowledged the GME mistake he made and that it should never occur again. Instant settlement with 24x7 trading. $MMTLP $NWBO $GNS $QNTM legal battles are showing the public and the regulators how flawed the present USA exchanges are. It’s why Citadel is trying to hide. Now think why Clayton, Atkins, Bessent, Nunes, Pulte, Blanche and Patel were all hand picked. Intentional due to their expertise. Clean markets are coming. The criminals have no say. https://x.com/vladtenev/status/2089813816611922368?s=46

0 · Reply

FickleFin Aug. 18 at 10:26 AM

$QNTM $GNS $GME Kevin is a fucking loser. A team charade to fuck over retail. Remember when he told everyone to DRS their shares? Same cringe feeling when they were offering FREE FRIES if you took the covid vaccine. They even took part of the covid sham.

0 · Reply

Market Cap	20.28M
Revenue (ttm)	0.00
Net Income (ttm)	-26.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	82,900
Avg Vol	189,586
Day's Range	N/A - N/A
Shares Out	6.40M
Stochastic %K	4%
Beta	0.45
Analysts	Strong Sell
Price Target	$21.75